Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk of developing severe symptoms.
Some treatments for lupus may also increase the risk of infections or severe complications from infections. Prevention is one of the most important tools against COVID-19, and there are some extra steps to consider for people with compromised immune systems.
It is important for people with lupus to work closely with their doctors to find workable treatments for their symptoms in each case.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.